نتایج جستجو برای: neprilysin
تعداد نتایج: 1663 فیلتر نتایج به سال:
The subunit c stoichiometry of Escherichia coli ATP synthase was studied by intermolecular cross-linking via oxidation of bi-cysteine-substituted subunit c (cA21C/cM65C). Independent of the carbon source used for growth and independent of the presence of other FoF1 subunits, an equal pattern of cross-link formation stopping at the formation of decamers was obtained.
OBJECTIVE In addition to the recent success of neprilysin inhibition in treatment heart failure, elevated soluble (sNEP) circulation has been suggested be a prognostic biomarker failure with reduced ejection fraction (HFrEF). However, diagnostic performance sNEP is nebulous and its levels HFrEF have not compared controls. For purpose this study, we determined role as routine ambulatory care pat...
Policy Aetna considers the following treatments for Alzheimer's disease (AD) experimental and investigational because their effectiveness for this indication has not been established (not an all inclusive list). Adoptive imunotherapy (see CPB 0641-Adoptive Immunotherapy and and Cellular Therapy) Applied behavior analysis Bapineuzumab Beta-amyloid degrading enzymes including cathepsin B, neprily...
Incorporation of neprilysin inhibition into heart failure pharmacotherapy regimens has recently been recommended by U.S. guidelines, based on results from the PARADIGM-HF trial comparing sacubitril/valsartan to enalapril. While most of the discussion has focused on efficacy, a closer examination of the safety results, particularly the incidence of angioedema during the run-in and double-blind p...
Heart failure remains a major concern across the globe as life expectancies and delivery of health care continue to improve. There has been a dearth of new developments in heart failure therapies in the last decade until last year, with the release of the results from the PARADIGM-HF Trial heralding the arrival of a promising new class of drug, ie, the angiotensin receptor-neprilysin inhibitor....
Heart failure (HF) is a syndrome whose cardinal symptoms are dyspnea and fatigue leading to a progressive decrease in exercise capacity. Drugs currently used include angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers (ARB), diuretics, alone or in combination, and in the cases where indicated, digoxin. Sacubitril/valsartan represents a new approach to treatment since the dru...
Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Neprilysin degrades several peptides that modulate lipid metabolism, including natriuretic peptides. In this study, we investigated the effects of 8 weeks' treatment with sacubitril/valsartan on whole-body and adipose tissue l...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید